Currently it only shows your basic business info. Start adding relevant business details such as description, images and products or services to gain your customers attention by using Boost 360
android app
/
iOS App/ web portal.
{
"products": [
{
"_id": "6891f29bfb7044dfb2d43adf",
"fptag": "STERISHEALTHCARE",
"merchantname": null,
"customwidgets": null,
"externalsourceid": null,
"name": "MAGRAL 160",
"description": "MAGRAL 160 is a pharmaceutical medication containing megestrol acetate 160 mg, a synthetic progestin known for its potent antineoplastic and appetite-stimulating properties. This drug is primarily prescribed to manage significant health challenges such as unexplained weight loss, anorexia, and cachexia, especially in patients suffering from chronic conditions like cancer or AIDS. Additionally, megestrol acetate functions as a hormone therapy agent employed in the treatment of certain hormone-sensitive malignancies. Its dual action both supports tumor management and improves patients' nutritional status by stimulating appetite and promoting weight gain, thereby enhancing overall quality of life. The drug is regarded as a crucial option in oncology and palliative care for managing complex conditions related to hormone-dependent cancers and severe wasting syndromes.\n\nWhat is MAGRAL 160?\nMAGRAL 160 is an oral medication formulated with megestrol acetate 160 mg, a synthetic progestin hormone derivative. It works primarily by modulating hormone receptors and altering hormone levels that influence the growth of hormone-responsive tumors such as breast and endometrial cancers. Apart from its antineoplastic action, it stimulates appetite by acting on the hypothalamic centers responsible for hunger, helping patients suffering from severe weight loss regain a healthy appetite and weight.\n\nUses of MAGRAL 160\n\nTo treat hormone-dependent cancers, specifically advanced breast cancer and endometrial cancer.\n\nTo stimulate appetite and promote weight gain in patients experiencing anorexia, cachexia, or unexplained severe weight loss related to chronic illnesses like cancer or AIDS.\n\nTo manage wasting syndromes that lead to malnutrition and significant weight loss.\n\nTo serve as an antineoplastic agent in hormone-sensitive malignancies.\n\nIn short, MAGRAL 160 is primarily used to treat anorexia and cachexia or serious unexplained weight loss and is also used as an antineoplastic agent to treat certain types of malignancy.\n\nSide Effects of MAGRAL 160\n\nWeight gain (often desirable but can be excessive)\n\nFluid retention and edema (swelling)\n\nNausea and vomiting\n\nDiarrhea or constipation\n\nVaginal bleeding or spotting in women\n\nFatigue, weakness, and insomnia\n\nHeadache and dizziness\n\nIncreased risk of blood clots (deep vein thrombosis or pulmonary embolism)\n\nHormonal imbalances, such as decreased sex hormone levels, which can lead to sexual dysfunction or bone density loss\n\nAllergic reactions including rash or itching\n\nPatients should report severe or unusual symptoms, especially signs of blood clots such as limb swelling, chest pain, or sudden shortness of breath, immediately to their healthcare provider.\n\nPrecautions before Using MAGRAL 160\n\nInform your doctor if you are pregnant, breastfeeding, or planning to conceive as MAGRAL 160 is contraindicated in pregnancy.\n\nDisclose any history of blood clots, cardiovascular diseases, liver or kidney impairment.\n\nPatients with diabetes should monitor blood sugar closely as megestrol acetate may cause hyperglycemia.\n\nAvoid sudden discontinuation without medical advice to prevent potential hormonal withdrawal effects.\n\nRegular monitoring is required, including hormone levels and blood tests, to assess efficacy and safety during treatment.\n\nUse cautiously in patients at risk for deep vein thrombosis or pulmonary embolism due to increased clotting risks.\n\nDrug Interactions: What Drugs Interact with MAGRAL 160?\n\nCYP3A4 enzyme inducers (e.g., rifampin, phenytoin) may reduce the effectiveness of megestrol acetate by increasing its metabolism.\n\nConcurrent use with blood thinners (anticoagulants) requires careful monitoring as MAGRAL 160 might influence clotting parameters.\n\nCombining with drugs that affect hormonal pathways, such as other hormonal therapies or corticosteroids, may alter treatment outcomes.\n\nInteractions with diabetes medications might necessitate dose adjustment due to potential effects on blood sugar control.\n\nCareful medical supervision is necessary when used with immunosuppressants or other chemotherapy agents to avoid additive side effects or altered drug levels.\n\nConclusion\nMAGRAL 160, containing megestrol acetate 160 mg, is a clinically validated medication widely used to manage complex conditions such as hormone-dependent cancers as well as severe weight loss due to anorexia and cachexia. Its unique ability to act both as an antineoplastic agent and an appetite stimulant makes it invaluable in improving patient outcomes, nutritional status, and overall quality of life. Patients prescribed MAGRAL 160 should adhere strictly to their healthcare provider’s instructions and report any adverse effects promptly. This medication should always be used under medical supervision to ensure optimal benefits and minimize risks.",
"price": 810.0,
"discountamount": 243.0,
"currencycode": "INR",
"priority": 1000000,
"isfreeshipmentavailable": false,
"shipmentduration": 1,
"_keywords": null,
"isarchived": false,
"isavailable": true,
"applicationid": null,
"productindex": 2156,
"imageuri": "https://productimages.withfloats.com/actual/6891f2a0115b51057b971998.png",
"tileimageuri": "https://productimages.withfloats.com/tile/6891f2a0115b51057b971998.png",
"images": null,
"totalqueries": 0,
"gpid": null,
"groupproductid": null,
"createdon": "2025-08-05T12:01:31.195Z",
"updatedon": "2025-08-05T12:01:31.195Z",
"buyonlinelink": null,
"producturl": "http://WWW.STERISINDIA.COM/products/magral-160/2156",
"availableunits": -1.0,
"iscodavailable": false,
"isprepaidonlineavailable": false,
"maxcodorders": 0,
"maxprepaidonlineorders": 0,
"uniquepaymenturl": null,
"brandname": "megestrol acetate 160 mg",
"category": "Gynaecology",
"tags": [
"megestrol acetate 160 mg"
],
"variants": false,
"keyspecification": null,
"otherspecifications": null,
"pickupaddressreferenceid": null,
"paymenttype": "UniquePaymentUrl",
"producttype": "products",
"hsncode": null,
"gstslab": 0.0,
"isnotforsale": false
},
{
"_id": "6890aa548a215c65672372e1",
"fptag": "STERISHEALTHCARE",
"merchantname": null,
"customwidgets": null,
"externalsourceid": null,
"name": "EMPATECH LINA 25/5",
"description": "EMPATECH LINA 25/5 is a pharmaceutical tablet containing a combination of two active ingredients: Empagliflozin 25MG and Linagliptin 5MG. This medication is designed to help manage blood sugar levels in adults with type 2 diabetes mellitus. The combination works through complementary mechanisms to improve glycemic control more effectively than either drug alone. Empagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor that promotes the excretion of excess glucose through urine, while Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances insulin secretion and suppresses glucagon release, particularly after meals. EMPATECH LINA 25/5 is generally prescribed alongside a balanced diet and regular exercise to optimize blood sugar management and reduce the risk of diabetes-related complications such as kidney damage, neuropathy, and cardiovascular issues.\n\nWhat is EMPATECH LINA 25/5?\n\nEMPATECH LINA 25/5 is a prescription medication combining Empagliflozin (25MG) and Linagliptin (5MG) tablets used to manage type 2 diabetes. It helps control elevated blood sugar levels by using dual actions — the removal of glucose via kidneys and improving pancreatic hormone responses. This combination aims to achieve better and sustained glycemic control, often necessary for patients who have inadequate blood sugar control with other treatments.\n\nUses of EMPATECH LINA 25/5\n\nTo improve blood sugar control in adults with type 2 diabetes, particularly when monotherapy is insufficient.\n\nOften used as a second-line therapy after metformin or when metformin is not tolerated.\n\nTo reduce HbA1c (hemoglobin A1c), an important measure of long-term glucose control.\n\nMay help reduce weight and blood pressure as empagliflozin aids in glucose excretion.\n\nSupports comprehensive diabetes management along with diet and exercise.\n\nPrevents or reduces the risk of diabetes-associated complications such as kidney disease, cardiovascular events, and nerve damage.\n\nSide Effects of EMPATECH LINA 25/5\n\nCommon side effects may include urinary tract infections and genital infections due to increased glucose in urine.\n\nIncreased urination and dehydration.\n\nDizziness or lightheadedness, especially when standing up quickly.\n\nHypoglycemia (low blood sugar), though rare with this combination.\n\nGastrointestinal symptoms such as nausea or diarrhea.\n\nPotential increased risk of ketoacidosis (a serious condition related to high blood acids) in rare cases.\n\nAllergic reactions, although uncommon, may occur and require prompt medical attention.\n\nPrecautions Before Using EMPATECH LINA 25/5\n\nInform your healthcare provider if you have kidney disease, liver problems, or a history of urinary tract infections.\n\nNot recommended for type 1 diabetes or diabetic ketoacidosis treatment.\n\nUse with caution if you are pregnant, planning to become pregnant, or breastfeeding.\n\nStay hydrated while on this medication to reduce the risk of dehydration and dizziness.\n\nInform your doctor about any history of pancreatitis or pancreas disorders.\n\nRegular monitoring of kidney function and blood sugar levels is advised during treatment.\n\nAvoid drinking excessive alcohol as it may increase side effects or risk of ketoacidosis.\n\nDrug Interactions: What Drugs Interact with EMPATECH LINA 25/5?\n\nOther antidiabetic medications, such as insulin or sulfonylureas, may increase the risk of hypoglycemia.\n\nDiuretics, blood pressure medications, and lithium may interact and increase side effects.\n\nDrugs that impair kidney function can affect empagliflozin’s efficacy and safety.\n\nCertain enzyme-inducing drugs may reduce linagliptin levels, lowering its effectiveness.\n\nConsult your healthcare provider for a full list of possible interactions and before starting any new medication, including over-the-counter drugs or supplements.\n\nConclusion\n\nEMPATECH LINA 25/5, containing Empagliflozin 25MG and Linagliptin 5MG, is an effective combination medication to treat high blood sugar levels caused by type 2 diabetes. Its dual-action approach targets different physiological mechanisms to improve blood glucose control, helping reduce the risks and complications associated with diabetes. While it is generally well-tolerated, awareness of possible side effects and drug interactions is important. Always use under medical supervision, alongside lifestyle modifications such as diet and exercise, for optimal diabetes management.",
"price": 345.0,
"discountamount": 104.0,
"currencycode": "INR",
"priority": 1000000,
"isfreeshipmentavailable": false,
"shipmentduration": 1,
"_keywords": null,
"isarchived": false,
"isavailable": true,
"applicationid": null,
"productindex": 2154,
"imageuri": "https://productimages.withfloats.com/actual/6890aa58dd0bc098c3220f4c.png",
"tileimageuri": "https://productimages.withfloats.com/tile/6890aa58dd0bc098c3220f4c.png",
"images": null,
"totalqueries": 0,
"gpid": null,
"groupproductid": null,
"createdon": "2025-08-04T12:40:52.619Z",
"updatedon": "2025-08-04T12:40:52.619Z",
"buyonlinelink": null,
"producturl": "http://WWW.STERISINDIA.COM/products/empatech-lina-25-5/2154",
"availableunits": -1.0,
"iscodavailable": false,
"isprepaidonlineavailable": false,
"maxcodorders": 0,
"maxprepaidonlineorders": 0,
"uniquepaymenturl": null,
"brandname": "Empagliflozin and Linagliptin Tablets",
"category": "DIABETIC RANGE",
"tags": [
"Empagliflozin and Linagliptin Tablets"
],
"variants": false,
"keyspecification": null,
"otherspecifications": null,
"pickupaddressreferenceid": null,
"paymenttype": "UniquePaymentUrl",
"producttype": "products",
"hsncode": null,
"gstslab": 0.0,
"isnotforsale": false
},
{
"_id": "67c5887fcd301704c9b6528a",
"fptag": "STERISHEALTHCARE",
"merchantname": null,
"customwidgets": null,
"externalsourceid": null,
"name": "Repaglinide 0.5mg",
"description": "RAPIGLINIDE 0.5 contains Repaglinide 0.5 mg, a medication used in the treatment of Type 2 diabetes mellitus. It belongs to a class of drugs known as meglitinides, which help control blood sugar levels by stimulating insulin production from the pancreas. RAPIGLINIDE is commonly prescribed to individuals who are unable to maintain optimal blood glucose levels through diet and exercise alone. It can be used alone or in combination with other oral diabetes medications to help manage blood sugar levels effectively.\n\n \nKey Benefits:\n \n Effective Blood Sugar Control – Helps lower postprandial blood glucose levels, effectively managing blood sugar spikes after meals.\n Rapid Action – Starts working quickly, offering fast relief from elevated blood sugar levels.\n Flexible Dosing – Can be taken before meals, giving flexibility in meal planning and diabetes management.\n Helps Prevent Complications of Diabetes – By controlling blood sugar levels, it helps in reducing the risk of complications associated with diabetes, such as nerve damage, heart disease, and kidney issues.\n Used Alone or with Other Diabetes Medications – RAPIGLINIDE 0.5 can be combined with other oral diabetes drugs for better blood sugar management.\n\n \nHow Does It Work?\n \n\nRepaglinide 0.5 mg works by stimulating the beta cells in the pancreas to secrete insulin when blood sugar levels rise after meals. The medication acts quickly, allowing the body to use glucose more effectively and preventing high blood sugar spikes. Unlike other long-acting insulin medications, Repaglinide acts quickly but for a short duration, making it suitable for controlling blood sugar right after eating. It helps in maintaining optimal postprandial glucose levels, which is crucial for the management of Type 2 diabetes.\n\n \nDirections for Use:\n \n\nTake RAPIGLINIDE 0.5 exactly as prescribed by your doctor.\nThe typical dosage is 0.5 mg to 2 mg taken before meals, 2 to 3 times daily.\nSwallow the tablet whole with water.\nDo not take more than the prescribed dose, and never skip doses.\nIf you miss a dose, take it as soon as you remember before the next meal. If it's almost time for your next meal, skip the missed dose—do not double the dose.\n \nSide Effects:\n \n\nWhile RAPIGLINIDE 0.5 is generally well-tolerated, some people may experience:\n\nHypoglycemia (low blood sugar): Symptoms include dizziness, sweating, shaking, confusion, and headaches.\nNausea or diarrhea\nWeight gain (in some cases)\nHeadache or dizziness\nRash or itching (rare)\nAbdominal discomfort\nIf you experience any signs of severe hypoglycemia (such as confusion, blurred vision, or seizures), or severe allergic reactions (such as difficulty breathing, swelling of the face or throat), seek immediate medical attention.",
"price": 217.0,
"discountamount": 66.0,
"currencycode": "INR",
"priority": 1000000,
"isfreeshipmentavailable": false,
"shipmentduration": 1,
"_keywords": [
"2 mg",
"05 mg",
"rapiglinide 05",
"meals 2",
"pancreas rapiglinide",
"repaglinide 05 mg",
"meal skip",
"prescribed dose",
"meal planning",
"commonly prescribed",
"medical attention",
"throat seek",
"dizziness rash",
"cases headache",
"headaches nausea",
"generally welltolerated",
"missed dosedo",
"skip doses",
"typical dosage",
"beta cells",
"kidney issues",
"repaglinide 05mgrapiglinide 05",
"severe hypoglycemia",
"secrete insulin",
"oral diabetes drugs",
"stimulating insulin production",
"meals giving flexibility",
"dose side effects",
"blood sugar management",
"oral diabetes medications",
"severe allergic reactions",
"difficulty breathing swelling",
"confusion blurred vision",
"diarrhea weight gain",
"controlling blood sugar",
"short duration making"
],
"isarchived": false,
"isavailable": true,
"applicationid": null,
"productindex": 2063,
"imageuri": "https://productimages.withfloats.com/actual/67c588a2587befa5fb853a41.png",
"tileimageuri": "https://productimages.withfloats.com/tile/67c588a2587befa5fb853a41.png",
"images": null,
"totalqueries": 0,
"gpid": null,
"groupproductid": null,
"createdon": "2025-03-03T10:46:23.834Z",
"updatedon": "2025-03-03T10:46:56.222Z",
"buyonlinelink": null,
"producturl": "http://WWW.STERISINDIA.COM/products/repaglinide-0-5mg/2063",
"availableunits": -1.0,
"iscodavailable": false,
"isprepaidonlineavailable": false,
"maxcodorders": 0,
"maxprepaidonlineorders": 0,
"uniquepaymenturl": null,
"brandname": "RAPIGLINIDE 0.5",
"category": "DIABETIC RANGE",
"tags": [
"Repaglinide 0.5 Mg Tablet Uses in Hindi",
"Repaglinide 0.5 mg tablet uses",
"Repaglinide 0.5 mg brand name",
"Repaglinide brand name",
"Repaglinide side effects 0.5 mg"
],
"variants": false,
"keyspecification": null,
"otherspecifications": null,
"pickupaddressreferenceid": null,
"paymenttype": "UniquePaymentUrl",
"producttype": "products",
"hsncode": null,
"gstslab": 0.0,
"isnotforsale": false
},
{
"_id": "67a35767912e6c5ba00a1473",
"fptag": "STERISHEALTHCARE",
"merchantname": null,
"customwidgets": null,
"externalsourceid": null,
"name": "Empagliflozin (5mg) ,Metformin Hydrochloride (500mg)",
"description": "GLIEMPAFLOZIN MET is an advanced oral medication designed for the effective management of Type 2 Diabetes Mellitus. This combination of Empagliflozin (5mg) and Metformin Hydrochloride (500mg) helps regulate blood sugar levels, improve insulin sensitivity, and reduce the risk of diabetes-related complications. It is commonly prescribed as part of a comprehensive diabetes care plan, including diet and lifestyle modifications.\n\n \nKey Benefits:\n \n\nEffective Blood Sugar Control – Helps maintain stable blood glucose levels.\nReduces Insulin Resistance – Enhances the body's ability to utilize insulin efficiently.\nPromotes Weight Management – Empagliflozin aids in weight loss by eliminating excess glucose.\nImproves Cardiovascular Health – Lowers the risk of heart disease in diabetic patients.\nSupports Kidney Function – Helps reduce the progression of diabetic kidney disease.\nLower Risk of Hypoglycemia – Unlike some other diabetes medications, it has a lower risk of causing dangerously low blood sugar levels.\n \nHow Does It Work?\n \n\nGLIEMPAFLOZIN MET combines two powerful antidiabetic agents to provide synergistic effects:\n\nEmpagliflozin (SGLT2 Inhibitor): Blocks glucose reabsorption in the kidneys, allowing excess sugar to be excreted through urine. This helps lower blood glucose levels effectively.\nMetformin (Biguanide): Works by decreasing glucose production in the liver and improving insulin sensitivity, leading to better glucose utilization by body tissues.\nTogether, these mechanisms help in long-term diabetes management, reducing complications and improving overall well-being.\n\n \nDirections for Use:\n \n\nTake one tablet as prescribed by your healthcare provider.\nPreferably consume with meals to minimize stomach discomfort.\nSwallow the tablet whole with water; do not crush or chew.\nMaintain a healthy diet and exercise routine for optimal results.\nRegular blood sugar monitoring is recommended to track progress.\n \nSide Effects:\n \n\nWhile GLIEMPAFLOZIN MET is generally well-tolerated, some individuals may experience:\n\nCommon Side Effects:\n\nNausea, vomiting, or diarrhea\nIncreased urination\nMild dehydration\nWeakness or dizziness\nSerious Side Effects (Seek Medical Attention):\n\nKetoacidosis: Unusual fatigue, nausea, vomiting, or breathing difficulties.\nUrinary Tract Infections (UTIs): Burning sensation while urinating, fever, or pelvic pain.\nLactic Acidosis (Rare but Severe): Muscle pain, trouble breathing, irregular heartbeat.\nIf any severe reactions occur, consult a doctor immediately.",
"price": 115.0,
"discountamount": 35.0,
"currencycode": "INR",
"priority": 1000000,
"isfreeshipmentavailable": false,
"shipmentduration": 1,
"_keywords": [
"lower risk",
"healthy diet",
"commonly prescribed",
"doctor immediately",
"urinating fever",
"generally welltolerated",
"gliempaflozin met",
"exercise routine",
"chew maintain",
"wellbeing directions",
"body tissues",
"diabetes medications",
"hypoglycemia unlike",
"heart disease",
"weight loss",
"bodys ability",
"diabetesrelated complications",
"empagliflozin 5mg",
"effective management",
"glucose utilization",
"decreasing glucose production",
"powerful antidiabetic agents"
],
"isarchived": false,
"isavailable": true,
"applicationid": null,
"productindex": 2043,
"imageuri": "https://productimages.withfloats.com/actual/67a35783a4575f9364b319c7.png",
"tileimageuri": "https://productimages.withfloats.com/tile/67a35783a4575f9364b319c7.png",
"images": null,
"totalqueries": 0,
"gpid": null,
"groupproductid": null,
"createdon": "2025-02-05T12:19:51.149Z",
"updatedon": "2025-03-22T10:21:42.769Z",
"buyonlinelink": null,
"producturl": "http://WWW.STERISINDIA.COM/products/empagliflozin-5mg-metformin-hydrochloride-500mg-/2043",
"availableunits": -1.0,
"iscodavailable": false,
"isprepaidonlineavailable": false,
"maxcodorders": 0,
"maxprepaidonlineorders": 0,
"uniquepaymenturl": null,
"brandname": "GLIEMPAFLOZIN MET 5MG/ 500MG ",
"category": "DIABETIC RANGE",
"tags": [
"empagliflozin/metformin 5 mg/1000 mg",
"empagliflozin + metformin combination brand name",
"Empagliflozin and metformin hydrochloride tablets",
"empagliflozin + metformin brand name in india",
"empagliflozin 12.5 mg+metformin 500 mg price"
],
"variants": false,
"keyspecification": null,
"otherspecifications": null,
"pickupaddressreferenceid": null,
"paymenttype": "UniquePaymentUrl",
"producttype": "products",
"hsncode": null,
"gstslab": 0.0,
"isnotforsale": false
},
{
"_id": "67122bef263d0316fb4c9dcb",
"fptag": "STERISHEALTHCARE",
"merchantname": null,
"customwidgets": null,
"externalsourceid": null,
"name": "Gliclazide IP (40 mg) , Pioglitazone Hydrochloride IP (15 mg) , Metformin Hydrochloride IP (500 mg)",
"description": "TRI-GLICLAGLAZE 40 is a powerful oral anti-diabetic medication formulated to manage Type 2 Diabetes Mellitus effectively. This combination of three potent drugs—Gliclazide, Pioglitazone, and Metformin—works synergistically to control high blood sugar levels, improve insulin sensitivity, and help patients achieve better glycemic control. TRI-GLICLAGLAZE 40 is designed for patients who struggle to manage blood glucose levels with single medications or lifestyle changes alone. It is a comprehensive solution for long-term diabetes management and reducing the risk of complications related to uncontrolled blood sugar.\n\n \n\nKey Benefits:\n \n\nEffective Blood Sugar Control: TRI-GLICLAGLAZE 40 helps maintain optimal blood glucose levels by targeting different aspects of diabetes management, such as stimulating insulin release, improving insulin sensitivity, and reducing glucose production.\nReduces Insulin Resistance: Pioglitazone and Metformin work together to lower insulin resistance, making it easier for the body to use insulin effectively.\nImproves Long-Term Glycemic Control: By combining three active ingredients, this medication is particularly beneficial for those struggling with glycemic control through diet or monotherapy alone.\nReduces Risk of Diabetes Complications: Controlling blood sugar levels helps prevent diabetes-related complications such as nerve damage, kidney disease, and cardiovascular problems.\nSupports Weight Management: Metformin, in particular, has been known to assist with weight management, which is important for patients with Type 2 Diabetes.\n \n\nHow Does It Work?\n \nTRI-GLICLAGLAZE 40 works through a multi-faceted mechanism to lower blood glucose levels:\n\nGliclazide stimulates the beta cells in the pancreas to release more insulin, which lowers blood sugar levels post-meal.\n\nPioglitazone enhances the body's sensitivity to insulin by promoting glucose uptake in the muscle and fat cells while also decreasing glucose production in the liver.\n\nMetformin reduces the production of glucose in the liver and improves insulin sensitivity. It also decreases the absorption of sugar from the intestines, ensuring better blood sugar control throughout the day.\n\nThis combination of ingredients targets multiple pathways involved in glucose regulation, making it an effective option for individuals with Type 2 Diabetes who require more comprehensive blood sugar control.\n\n \n\nDirections for Use:\n \nTake TRI-GLICLAGLAZE 40 exactly as prescribed by your doctor.\nUsually, it is taken once or twice daily with meals to minimize gastrointestinal discomfort.\nSwallow the tablet whole with water—do not crush or chew the tablet.\nContinue following your diet and exercise plan alongside the medication to achieve optimal blood sugar control.\nDo not skip doses, and consult your healthcare provider if you miss a dose.\n \n\nSide Effects:\n \nLike any medication, TRI-GLICLAGLAZE 40 may cause side effects, although not everyone experiences them. Some common and mild side effects include:\n\nHypoglycemia (Low Blood Sugar): Due to Gliclazide’s insulin-stimulating properties, low blood sugar may occur, especially if meals are skipped or exercise is excessive.\n\nGastrointestinal Issues: Metformin is known to cause digestive problems in some individuals, including nausea, vomiting, diarrhea, or stomach cramps.\n\nWeight Gain: Pioglitazone may cause weight gain in some users due to increased fat storage.\n\nFluid Retention: Pioglitazone may lead to water retention, especially in patients with heart conditions, increasing the risk of heart failure.\n\nHeadache and dizziness: These may occur as the body adjusts to the medication, but they are generally mild and temporary.\n\nLactic Acidosis (rare): A serious but rare side effect of Metformin, this condition requires immediate medical attention and is characterized by muscle pain, breathing difficulties, and weakness.\n\n ",
"price": 145.0,
"discountamount": 43.5,
"currencycode": "INR",
"priority": 1000000,
"isfreeshipmentavailable": false,
"shipmentduration": 7,
"_keywords": [
"fat cells",
"beta cells",
"muscle pain",
"fat storage",
"Weight Gain",
"nerve damage",
"Key Benefits",
"exercise plan",
"Gliclazide IP",
"heart failure",
"stomach cramps",
"kidney disease",
"glucose uptake",
"water retention",
"insulin release",
"Lactic Acidosis",
"Fluid Retention",
"Low Blood Sugar",
"heart conditions",
"rare side effect",
"multiple pathways",
"different aspects",
"lifestyle changes",
"Weight Management",
"mild side effects",
"Insulin Resistance",
"digestive problems",
"single medications",
"glucose production",
"glucose regulation",
"three potent drugs",
"insulin sensitivity",
"healthcare provider",
"breathing difficulties",
"Diabetes Complications",
"comprehensive solution",
"Metformin Hydrochloride",
"Gastrointestinal Issues",
"multi-faceted mechanism",
"cardiovascular problems",
"high blood sugar levels",
"Type 2 Diabetes Mellitus",
"three active ingredients",
"uncontrolled blood sugar",
"Long-Term Glycemic Control",
"gastrointestinal discomfort",
"immediate medical attention",
"optimal blood sugar control",
"optimal blood glucose levels",
"Pioglitazone Hydrochloride IP",
"long-term diabetes management",
"Effective Blood Sugar Control",
"diabetes-related complications",
"insulin-stimulating properties",
"comprehensive blood sugar control",
"powerful oral anti-diabetic medication"
],
"isarchived": false,
"isavailable": true,
"applicationid": null,
"productindex": 1994,
"imageuri": "https://productimages.withfloats.com/actual/67122bf4ac30f07ce03345d7.png",
"tileimageuri": "https://productimages.withfloats.com/tile/67122bf4ac30f07ce03345d7.png",
"images": null,
"totalqueries": 0,
"gpid": null,
"groupproductid": null,
"createdon": "2024-10-18T09:35:43.008Z",
"updatedon": "2024-10-18T09:35:43.008Z",
"buyonlinelink": null,
"producturl": "http://WWW.STERISINDIA.COM/products/gliclazide-ip-40-mg-pioglitazone-hydrochloride-ip-15-mg-metformin-hydrochloride-ip-500-mg-/1994",
"availableunits": -1.0,
"iscodavailable": false,
"isprepaidonlineavailable": false,
"maxcodorders": 0,
"maxprepaidonlineorders": 0,
"uniquepaymenturl": null,
"brandname": "TRI - GLICLAGLAZE 40 ",
"category": "DIABETIC RANGE",
"tags": [
"gliclazide+metformin hydrochloride tablets uses",
"Gliclazide Metformin Pioglitazone brand name",
"Gliclazide and Metformin hydrochloride tablets Use",
"Gliclazide and Metformin Hydrochloride tablets pri",
"Gliclazide and Metformin Hydrochloride Tablets bra",
"Gliclazide 80 mg and Metformin Hydrochloride table",
"",
""
],
"variants": false,
"keyspecification": null,
"otherspecifications": null,
"pickupaddressreferenceid": "",
"paymenttype": "UniquePaymentUrl",
"producttype": "products",
"hsncode": null,
"gstslab": 0.0,
"isnotforsale": false
},
{
"_id": "66ed2340847254d7d1081d9a",
"fptag": "STERISHEALTHCARE",
"merchantname": null,
"customwidgets": null,
"externalsourceid": null,
"name": "Sitagliptin Tablet IP 25 mg",
"description": "ST GLIPTIN 25 is a pharmaceutical product containing Sitagliptin, an effective medication used to control blood sugar levels in individuals with Type 2 diabetes mellitus. It belongs to a class of drugs known as DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors). This medication is often prescribed in combination with other antidiabetic drugs or diet and exercise plans to help manage blood sugar levels and reduce the risk of complications associated with diabetes, such as heart disease, nerve damage, and kidney problems.\n\n \nKey Ingredients:\n \n\nSitagliptin Tablet IP 25 mg: The active ingredient Sitagliptin works by increasing the levels of incretin hormones, which help regulate insulin production in response to meals. It also lowers the amount of glucose produced by the liver.\n \nKey Benefits:\n \n\nEffective Blood Sugar Control: ST GLIPTIN 25 helps to manage blood sugar levels in adults with Type 2 diabetes, especially when used alongside proper diet and exercise.\nMinimal Risk of Hypoglycemia: Unlike some other diabetes medications, Sitagliptin generally does not cause hypoglycemia (low blood sugar) when used alone.\nPromotes Healthy Insulin Levels: Sitagliptin helps enhance the body’s natural release of insulin after meals, improving overall glucose management.\nSupports Heart Health: Maintaining stable blood sugar levels can reduce the risk of cardiovascular complications, making it an important part of a diabetes management plan.\n \nHow Does It Work?\n \n\nST GLIPTIN 25 (Sitagliptin) works by inhibiting the DPP-4 enzyme, which is responsible for breaking down incretin hormones. These hormones play a key role in regulating blood glucose levels by stimulating insulin release and decreasing glucose production in the liver. By inhibiting DPP-4, Sitagliptin increases the levels of active incretin hormones, leading to better control over blood sugar levels, especially after meals.\n\n \nDirections for Use:\n \n\nDosage: The recommended dose is typically 25 mg taken once daily, as directed by your healthcare provider. This dosage may be adjusted based on the individual's health condition and response to treatment.\nMethod: ST GLIPTIN 25 can be taken with or without food. Swallow the tablet whole with a glass of water. To achieve the best results, it's important to take the medication at the same time each day.\nConsistency: It's essential to continue taking ST GLIPTIN 25 as prescribed, even if you feel well. Do not stop the medication without consulting your doctor.\n \nSide Effects:\n \n\nWhile ST GLIPTIN 25 is generally well-tolerated, some individuals may experience side effects such as:\n\nNausea or diarrhea\nHeadache\nUpper respiratory tract infections\nSore throat\nJoint pain",
"price": 69.0,
"discountamount": 20.7,
"currencycode": "INR",
"priority": 1000000,
"isfreeshipmentavailable": false,
"shipmentduration": 7,
"_keywords": [
"key role",
"same time",
"Joint pain",
"ST GLIPTIN",
"proper diet",
"Sore throat",
"Minimal Risk",
"DPP-4 enzyme",
"Side Effects",
"best results",
"Heart Health",
"Key Benefits",
"nerve damage",
"heart disease",
"exercise plans",
"insulin release",
"natural release",
"Key Ingredients",
"kidney problems",
"low blood sugar",
"health condition",
"DPP-4 inhibitors",
"active ingredient",
"insulin production",
"glucose production",
"healthcare provider",
"effective medication",
"blood glucose levels",
"Sitagliptin Tablet IP",
"pharmaceutical product",
"Healthy Insulin Levels",
"active incretin hormones",
"Type 2 diabetes mellitus",
"other antidiabetic drugs",
"diabetes management plan",
"stable blood sugar levels",
"overall glucose management",
"other diabetes medications",
"cardiovascular complications",
"Effective Blood Sugar Control",
"dipeptidyl peptidase-4 inhibitors",
"Upper respiratory tract infections"
],
"isarchived": false,
"isavailable": true,
"applicationid": null,
"productindex": 1978,
"imageuri": "https://productimages.withfloats.com/actual/66ed23433e1478b5013cfd1c.png",
"tileimageuri": "https://productimages.withfloats.com/tile/66ed23433e1478b5013cfd1c.png",
"images": null,
"totalqueries": 0,
"gpid": null,
"groupproductid": null,
"createdon": "2024-09-20T07:24:48.197Z",
"updatedon": "2024-09-20T07:28:37.557Z",
"buyonlinelink": null,
"producturl": "http://WWW.STERISINDIA.COM/products/sitagliptin-tablet-ip-25-mg/1978",
"availableunits": -1.0,
"iscodavailable": false,
"isprepaidonlineavailable": false,
"maxcodorders": 0,
"maxprepaidonlineorders": 0,
"uniquepaymenturl": null,
"brandname": "ST GLIPTIN 25 ",
"category": "DIABETIC RANGE",
"tags": [
"What is gliptin used for?",
"",
"What is the use of S gliptin tablet?"
],
"variants": false,
"keyspecification": null,
"otherspecifications": null,
"pickupaddressreferenceid": "",
"paymenttype": "UniquePaymentUrl",
"producttype": "products",
"hsncode": null,
"gstslab": 0.0,
"isnotforsale": false
},
{
"_id": "668e8611b9f7300708fe1240",
"fptag": "STERISHEALTHCARE",
"merchantname": null,
"customwidgets": null,
"externalsourceid": null,
"name": "TRIOGLIMITERIS 1/0.2 ",
"description": "TRIOGLIMITERIS 1/0.2 \nVoglibose 0.2 mg, Glimepiride 1 mg & Metformin Hydrochloride 500 mg\nIntroduction\n\nTRIOGLIMITERIS 1/0.2 is a combination medication containing Voglibose, Glimepiride, and Metformin Hydrochloride. It is primarily used in the management of type 2 diabetes mellitus to improve glycemic control through different mechanisms of action targeting glucose metabolism.\n\nComposition\n\nVoglibose (0.2 mg): An alpha-glucosidase inhibitor that delays the digestion of carbohydrates in the intestine, thereby reducing postprandial blood glucose levels.\nGlimepiride (1 mg): A sulfonylurea derivative that stimulates insulin release from pancreatic beta cells, enhancing glucose uptake in peripheral tissues.\nMetformin Hydrochloride (500 mg): A biguanide that decreases hepatic glucose production, improves insulin sensitivity in peripheral tissues, and reduces intestinal glucose absorption.\nMechanism of Action\n\nTRIOGLIMITERIS 1/0.2 combines the actions of its components to achieve optimal glycemic control:\n\nVoglibose: Inhibits alpha-glucosidase enzymes in the intestine, delaying carbohydrate digestion and reducing the absorption of glucose after meals.\nGlimepiride: Stimulates insulin secretion from pancreatic beta cells in a glucose-dependent manner, thereby lowering blood glucose levels.\nMetformin Hydrochloride: Decreases hepatic glucose production through suppression of gluconeogenesis and enhances peripheral glucose uptake and utilization by improving insulin sensitivity.\nIndications\n\nTRIOGLIMITERIS 1/0.2 is indicated for:\n\nType 2 Diabetes Mellitus: Used to improve glycemic control in adults when diet, exercise, and monotherapy with metformin or sulfonylureas alone are not sufficient.\nDosage and Administration\n\nThe typical dosage of TRIOGLIMITERIS 1/0.2 is one tablet taken orally with meals, usually once or twice daily.\nDosage adjustments may be required based on individual patient response, blood glucose levels, and renal function.\nIt is essential to adhere to the prescribed dosage regimen to achieve optimal therapeutic outcomes.\nSide Effects\n\nCommon side effects of TRIOGLIMITERIS 1/0.2 may include:\n\nHypoglycemia (especially when used in combination with insulin or other antidiabetic medications)\nGastrointestinal disturbances (such as nausea, vomiting, diarrhea, or abdominal discomfort)\nWeight gain (mainly associated with sulfonylureas)\nMore severe side effects can include:\n\nAllergic reactions (rash, itching, swelling)\nLactic acidosis (rare but serious adverse effect associated with metformin use)\nHepatic dysfunction (monitor liver function tests periodically)\nPrecautions\n\nUse with caution in patients with renal impairment, hepatic dysfunction, or other significant medical conditions that may affect drug metabolism or excretion.\nRegular monitoring of blood glucose levels, renal function, and liver function is recommended during treatment with TRIOGLIMITERIS 1/0.2.\nAvoid use in patients with type 1 diabetes mellitus or diabetic ketoacidosis.\nDrug Interactions\n\nTRIOGLIMITERIS 1/0.2 may interact with other medications affecting blood glucose levels, such as insulin, other oral antidiabetic agents, or drugs that affect renal function or hepatic metabolism. Close monitoring and dose adjustments may be necessary.\nConclusion\n\nTRIOGLIMITERIS 1/0.2 provides a comprehensive approach to managing type 2 diabetes mellitus by combining Voglibose, Glimepiride, and Metformin Hydrochloride. This combination targets different aspects of glucose metabolism, enhancing insulin secretion, reducing hepatic glucose production, and delaying carbohydrate absorption in the intestine. Proper dosage, administration, and monitoring for side effects are essential to achieve and maintain optimal glycemic control in diabetic patients using TRIOGLIMITERIS 1/0.2. Consultation with a healthcare provider is recommended for personalized treatment plans and management of diabetes with this medication.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order NOW\n",
"price": 195.0,
"discountamount": 58.5,
"currencycode": "INR",
"priority": 1000000,
"isfreeshipmentavailable": false,
"shipmentduration": 7,
"_keywords": [
"500 mg",
"0.2 mg",
"one tablet",
"Weight gain",
"Glimepiride 1",
"metformin use",
"Proper dosage",
"Glimepiride (1",
"dosage regimen",
"typical dosage",
"renal function",
"insulin release",
"drug metabolism",
"Lactic acidosis",
"Close monitoring",
"dose adjustments",
"renal impairment",
"diabetic patients",
"insulin secretion",
"different aspects",
"Drug Interactions",
"other medications",
"Regular monitoring",
"Dosage adjustments",
"Allergic reactions",
"peripheral tissues",
"hepatic metabolism",
"glucose metabolism",
"insulin sensitivity",
"healthcare provider",
"Hepatic dysfunction",
"Common side effects",
"abdominal discomfort",
"different mechanisms",
"liver function tests",
"diabetic ketoacidosis",
"pancreatic beta cells",
"combination medication",
"carbohydrate digestion",
"comprehensive approach",
"serious adverse effect",
"Metformin Hydrochloride",
"carbohydrate absorption",
"sulfonylurea derivative",
"glucose-dependent manner",
"optimal glycemic control",
"type 1 diabetes mellitus",
"type 2 diabetes mellitus",
"More severe side effects",
"alpha-glucosidase enzymes",
"peripheral glucose uptake",
"hepatic glucose production",
"alpha-glucosidase inhibitor",
"individual patient response",
"personalized treatment plans",
"optimal therapeutic outcomes",
"Gastrointestinal disturbances",
"intestinal glucose absorption",
"other antidiabetic medications",
"other oral antidiabetic agents",
"postprandial blood glucose levels",
"other significant medical conditions"
],
"isarchived": false,
"isavailable": true,
"applicationid": null,
"productindex": 1939,
"imageuri": "https://productimages.withfloats.com/actual/668e86143a68154e11e7d822.jpeg",
"tileimageuri": "https://productimages.withfloats.com/tile/668e86143a68154e11e7d822.jpeg",
"images": null,
"totalqueries": 0,
"gpid": null,
"groupproductid": null,
"createdon": "2024-07-10T13:01:05.875Z",
"updatedon": "2024-07-10T13:01:05.875Z",
"buyonlinelink": null,
"producturl": "http://WWW.STERISINDIA.COM/products/trioglimiteris-1-0-2-/1939",
"availableunits": -1.0,
"iscodavailable": false,
"isprepaidonlineavailable": false,
"maxcodorders": 0,
"maxprepaidonlineorders": 0,
"uniquepaymenturl": null,
"brandname": "TRIOGLIMITERIS 1/0.2 ",
"category": "DIABETIC RANGE",
"tags": [
"glimepiride 1mg+metformin 500mg+voglibose 0.2 mg",
"Glimepiride 2mg Metformin 500mg Voglibose 0.2 mg b",
"glimepiride 2mg+metformin 500mg+voglibose 0.2 mg",
"voglibose glimepiride & metformin hydrochloride (s",
"voglibose glimepiride + metformin hydrochloride us",
"glimepiride 1mg+metformin 500mg+voglibose 0.3 mg",
"glimepiride 2mg+metformin 500mg+voglibose 0.2 mg g",
""
],
"variants": false,
"keyspecification": null,
"otherspecifications": null,
"pickupaddressreferenceid": "",
"paymenttype": "UniquePaymentUrl",
"producttype": "products",
"hsncode": null,
"gstslab": 0.0,
"isnotforsale": false
},
{
"_id": "668d24ff75f1701d34699e32",
"fptag": "STERISHEALTHCARE",
"merchantname": null,
"customwidgets": null,
"externalsourceid": null,
"name": "GLICLAGLAZE 80 ",
"description": "GLICLAGLAZE 80 \nGliclazide (80mg)\nOverview\nGLICLAGLAZE 80 is an oral medication containing Gliclazide at a dosage of 80 mg. Gliclazide belongs to the class of drugs known as sulfonylureas and is primarily used to manage type 2 diabetes mellitus. It helps control blood sugar levels by stimulating the release of insulin from the pancreatic beta cells. GLICLAGLAZE 80 is an effective treatment option for individuals who require oral hypoglycemic therapy to maintain optimal blood glucose levels.\n\nBenefits of Gliclazide\n\nBlood Sugar Control\n\nGliclazide effectively lowers blood glucose levels by increasing insulin secretion.\nHelps prevent complications associated with diabetes, such as neuropathy, nephropathy, and retinopathy.\nReduced Risk of Hypoglycemia\n\nCompared to some other sulfonylureas, Gliclazide has a lower risk of causing hypoglycemia (low blood sugar levels).\nIt provides a balanced approach to managing blood sugar without causing excessive drops in glucose levels.\nCardiovascular Benefits\n\nStudies suggest that Gliclazide may have a protective effect on the cardiovascular system.\nIt may reduce the risk of cardiovascular events in diabetic patients, promoting overall heart health.\nImproved Glycemic Control\n\nHelps achieve and maintain target HbA1c levels, reflecting long-term glycemic control.\nCan be used in combination with other oral antidiabetic agents or insulin to enhance its effectiveness.\nUsage and Dosage\nGLICLAGLAZE 80 should be taken as prescribed by a healthcare professional. The typical starting dose is 40 to 80 mg daily, which can be adjusted based on the patient's blood glucose response. It is usually taken with meals to maximize its effectiveness and minimize gastrointestinal side effects. Consistent use and adherence to prescribed dosage are crucial for optimal results.\n\nIndications for Use\n\nType 2 Diabetes Mellitus: GLICLAGLAZE 80 is indicated for the management of type 2 diabetes in patients who cannot achieve adequate glycemic control through diet and exercise alone.\nCombination Therapy: It can be used in conjunction with other oral hypoglycemic agents or insulin to achieve better blood sugar control.\nSide Effects\nGLICLAGLAZE 80 is generally well-tolerated. However, some patients may experience side effects, including:\n\nHypoglycemia: Although less common, low blood sugar can occur, especially if meals are skipped or combined with excessive physical activity.\nGastrointestinal Issues: Nausea, abdominal pain, and diarrhea may occur but are usually mild and transient.\nAllergic Reactions: Rarely, allergic reactions such as skin rash, itching, or hives may occur.\nPrecautions and Contraindications\n\nLiver and Kidney Impairment: Patients with severe liver or kidney disease should use GLICLAGLAZE 80 with caution, as it may require dose adjustments.\nPregnancy and Lactation: Gliclazide is not recommended during pregnancy or breastfeeding. Alternative treatments should be considered.\nDrug Interactions: Inform your healthcare provider about all medications and supplements you are taking, as Gliclazide can interact with other drugs, potentially altering its effectiveness.\nConclusion\nGLICLAGLAZE 80 is a reliable and effective oral medication for managing type 2 diabetes mellitus. By stimulating insulin secretion, it helps control blood sugar levels, reducing the risk of diabetes-related complications. Its balanced approach to glycemic control, combined with potential cardiovascular benefits, makes GLICLAGLAZE 80 a valuable addition to diabetes management plans. Under the guidance of a healthcare professional, GLICLAGLAZE 80 can significantly improve the quality of life for individuals with type 2 diabetes, promoting better long-term health outcomes.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order NOW\n",
"price": 265.0,
"discountamount": 79.5,
"currencycode": "INR",
"priority": 1000000,
"isfreeshipmentavailable": false,
"shipmentduration": 7,
"_keywords": [
"skin rash",
"lower risk",
"40 to 80 mg",
"other drugs",
"severe liver",
"Reduced Risk",
"Consistent use",
"kidney disease",
"abdominal pain",
"excessive drops",
"optimal results",
"dose adjustments",
"diabetic patients",
"insulin secretion",
"valuable addition",
"Drug Interactions",
"Kidney Impairment",
"protective effect",
"balanced approach",
"Allergic Reactions",
"healthcare provider",
"Combination Therapy",
"other sulfonylureas",
"Blood Sugar Control",
"target HbA1c levels",
"overall heart health",
"cardiovascular events",
"cardiovascular system",
"typical starting dose",
"pancreatic beta cells",
"Alternative treatments",
"blood glucose response",
"low blood sugar levels",
"healthcare professional",
"Gastrointestinal Issues",
"type 2 diabetes mellitus",
"diabetes management plans",
"adequate glycemic control",
"effective oral medication",
"long-term health outcomes",
"oral hypoglycemic therapy",
"long-term glycemic control",
"effective treatment option",
"excessive physical activity",
"optimal blood glucose levels",
"gastrointestinal side effects",
"diabetes-related complications",
"other oral hypoglycemic agents",
"other oral antidiabetic agents",
"potential cardiovascular benefits"
],
"isarchived": false,
"isavailable": true,
"applicationid": null,
"productindex": 1922,
"imageuri": "https://productimages.withfloats.com/actual/668d2505c34ba6457aa3fb4d.jpeg",
"tileimageuri": "https://productimages.withfloats.com/tile/668d2505c34ba6457aa3fb4d.jpeg",
"images": null,
"totalqueries": 0,
"gpid": null,
"groupproductid": null,
"createdon": "2024-07-09T11:54:39.186Z",
"updatedon": "2024-07-09T11:54:39.186Z",
"buyonlinelink": null,
"producturl": "http://WWW.STERISINDIA.COM/products/gliclaglaze-80-/1922",
"availableunits": -1.0,
"iscodavailable": false,
"isprepaidonlineavailable": false,
"maxcodorders": 0,
"maxprepaidonlineorders": 0,
"uniquepaymenturl": null,
"brandname": "GLICLAGLAZE 80 ",
"category": "DIABETIC RANGE",
"tags": [
"Gliclazide 80mg side effects",
"Gliclazide 80mg dosage",
"Gliclazide 80mg Metformin 500mg",
"Gliclazide 80mg price",
"Gliclazide 80mg uses",
"Gliclazide 80mg Uses in Hindi",
"Gliclazide 80mg before or after meal"
],
"variants": false,
"keyspecification": null,
"otherspecifications": null,
"pickupaddressreferenceid": "",
"paymenttype": "UniquePaymentUrl",
"producttype": "products",
"hsncode": null,
"gstslab": 0.0,
"isnotforsale": false
},
{
"_id": "6662cd3e870e7b20c49e689e",
"fptag": "STERISHEALTHCARE",
"merchantname": null,
"customwidgets": null,
"externalsourceid": null,
"name": "VOGLIGOLD G3 M0.3 ",
"description": "VOGLIGOLD G3 M0.3 \nVoglibose 0.3 mg, Glimepiride 3 mg & Metformin Hydrochloride 500 mg\nIntroduction to VOGLIGOLD G3 M0.3\nVOGLIGOLD G3 M0.3 is a combination medication designed for the effective management of type 2 diabetes mellitus. It contains three active ingredients: Voglibose 0.3mg, Glimepiride 3mg, and Metformin Hydrochloride 500mg. This multi-action formula targets different aspects of glucose regulation to provide comprehensive blood sugar control. It is used alongside diet and exercise to improve glycemic control in adults with type 2 diabetes.\n\nKey Components and Their Mechanisms\nVoglibose 0.3mg\nVoglibose is an alpha-glucosidase inhibitor that works by:\n\nSlowing Carbohydrate Absorption: Voglibose inhibits the alpha-glucosidase enzyme in the small intestine, delaying the breakdown of complex carbohydrates into glucose. This helps to smooth out postprandial (after-meal) blood glucose peaks.\nGlimepiride 3mg\nGlimepiride is a sulfonylurea that helps control blood sugar by:\n\nStimulating Insulin Secretion: Glimepiride stimulates the pancreas to release more insulin, which helps lower blood sugar levels, particularly after meals.\nMetformin Hydrochloride 500mg\nMetformin is a biguanide that helps lower blood sugar levels through several mechanisms:\n\nReducing Hepatic Glucose Production: Metformin decreases the amount of glucose produced by the liver.\nImproving Insulin Sensitivity: It enhances the sensitivity of muscle cells to insulin, promoting better glucose uptake and utilization.\nDecreasing Intestinal Absorption of Glucose: Metformin reduces the absorption of glucose from the gastrointestinal tract.\nBenefits of VOGLIGOLD G3 M0.3\nComprehensive Blood Sugar Control\nFasting and Postprandial Glucose Management: The combination of Voglibose, Glimepiride, and Metformin effectively manages both fasting and postprandial blood sugar levels.\nEnhanced Insulin Secretion and Sensitivity: Glimepiride enhances insulin secretion, while Metformin improves insulin sensitivity, and Voglibose slows carbohydrate absorption.\nAdditional Health Benefits\nLow Risk of Hypoglycemia: The risk of hypoglycemia is minimized due to the complementary actions of the three components.\nWeight Neutrality: Metformin and Voglibose are generally weight neutral, making this combination favorable for patients concerned about weight gain associated with diabetes medications.\nHow to Use VOGLIGOLD G3 M0.3\nDosage and Administration\nRecommended Dosage: The typical dosage is one tablet taken once or twice daily, as prescribed by your healthcare provider.\nAdministration: Take the tablet with meals to reduce gastrointestinal side effects and enhance the absorption of Metformin. Swallow the tablet whole with a glass of water.\nGuidelines for Optimal Use\nConsistent Use: For best results, take VOGLIGOLD G3 M0.3 regularly at the same time each day as prescribed by your healthcare provider.\nMonitor Blood Sugar Levels: Regular monitoring of blood sugar levels is essential to ensure the medication is effectively controlling your diabetes. Adjustments to your treatment plan may be necessary based on these readings.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/vogligold-g3-m0-3-134319",
"price": 185.0,
"discountamount": 55.5,
"currencycode": "INR",
"priority": 1000000,
"isfreeshipmentavailable": false,
"shipmentduration": 7,
"_keywords": [
"meal",
"diet",
"Order",
"glass",
"water",
"EMAIL",
"liver",
"adults",
"amount",
"Fasting",
"readings",
"patients",
"pancreas",
"Low Risk",
"exercise",
"breakdown",
"same time",
"biguanide",
"Decreasing",
"one tablet",
"Guidelines",
"Glimepiride",
"Adjustments",
"weight gain",
"information",
"utilization",
"Optimal Use",
"best results",
"Introduction",
"sterispharma",
"sulfonylurea",
"Hypoglycemia",
"muscle cells",
"sterisonline",
"CALL/WHATSAPP",
"Voglibose 0.3",
"Administration",
"typical dosage",
"glucose uptake",
"treatment plan",
"Consistent Use",
"Key Components",
"small intestine",
"glycemic control",
"three components",
"VOGLIGOLD G3 M0.3",
"different aspects",
"Weight Neutrality",
"several mechanisms",
"glucose regulation",
"Regular monitoring",
"Recommended Dosage",
"blood glucose peaks",
"Insulin Sensitivity",
"healthcare provider",
"diabetes medications",
"effective management",
"multi-action formula",
"complex carbohydrates",
"Intestinal Absorption",
"complementary actions",
"gastrointestinal tract",
"combination medication",
"Metformin Hydrochloride",
"Carbohydrate Absorption",
"alpha-glucosidase enzyme",
"three active ingredients",
"type 2 diabetes mellitus",
"Enhanced Insulin Secretion",
"Additional Health Benefits",
"Hepatic Glucose Production",
"alpha-glucosidase inhibitor",
"gastrointestinal side effects",
"Postprandial Glucose Management",
"postprandial blood sugar levels",
"comprehensive blood sugar control"
],
"isarchived": false,
"isavailable": true,
"applicationid": null,
"productindex": 1519,
"imageuri": "https://productimages.withfloats.com/actual/667d30b6c303c6d6ad136ea4.png",
"tileimageuri": "https://productimages.withfloats.com/tile/667d30b6c303c6d6ad136ea4.png",
"images": null,
"totalqueries": 0,
"gpid": null,
"groupproductid": null,
"createdon": "2024-06-07T09:05:02.904Z",
"updatedon": "2024-06-27T09:28:16.215Z",
"buyonlinelink": null,
"producturl": "http://WWW.STERISINDIA.COM/products/vogligold-g3-m0-3-/1519",
"availableunits": -1.0,
"iscodavailable": false,
"isprepaidonlineavailable": false,
"maxcodorders": 0,
"maxprepaidonlineorders": 0,
"uniquepaymenturl": null,
"brandname": "VOGLIGOLD G3 M0.3 ",
"category": "DIABETIC RANGE",
"tags": [
"glimepiride 3mg+metformin 500mg+voglibose 0.3 mg",
"voglibose glimepiride + metformin hydrochloride us",
"glimepiride 2mg+metformin 500mg+voglibose 0.2 mg"
],
"variants": false,
"keyspecification": null,
"otherspecifications": null,
"pickupaddressreferenceid": "",
"paymenttype": "UniquePaymentUrl",
"producttype": "products",
"hsncode": null,
"gstslab": 0.0,
"isnotforsale": false
}
],
"hasmoreitems": false,
"isapirequest": false,
"totalresults": 27,
"query": null,
"floatingpoint": null
}